Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".[2] In India it is marketed under the brand name of Ibset.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth (ODT), IV |
ATC code |
|
Pharmacokinetic data | |
Elimination half-life | 5.8 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C17H17N3O |
Molar mass | 279.343 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5] While ramosetron itself may relief diarrhea for IBS patients, all the above tablets contain lactose, making them unsuitable for an IBS treatment in most cases.